# Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review

- R Whale Institute of Postgraduate Medicine, Brighton and Sussex Medical School, Brighton, UK.
- T Terao Department of Neuropsychiatry, Oita University, Oita, Japan.
- P Cowen Department of Psychiatry, University of Oxford, Oxford, UK.
- N Freemantle Health Care Evaluation Group, University of Birmingham, Birmingham, UK.
- J Geddes Department of Psychiatry, University of Oxford, Oxford, UK.

# Abstract

Adding pindolol to serotonergic antidepressant treatment offers a potential strategy for producing a more rapid onset of action and an enhanced antidepressant effect. This review investigated whether pindolol enhances the efficacy of serotonergic antidepressant treatment in adult patients with depressive disorders at sequential time points up to 6 weeks. *Search strategy*: Cochrane Collaboration Depression, Anxiety and Neurosis-Controlled Trials Register plus unpublished trial data. *Study selection*: Randomised trials including depressed patients, comparing serotonergic antidepressants + pindolol with serotonergic antidepressants + placebo and using depressive symptom clinical outcomes scales. *Data extraction*: Clinical response at time points up to 6 weeks as defined by >50% depression scale score reduction was extracted for each trial as possible. Eleven studies were identified including unpublished data. The pooled

odds ratios for dichotomous response to treatment at time points from 1 to 6 weeks were 2.39 (95% CI 1.40–4.06), 2.39 (1.74–3.29), 1.94 (1.46–2.58), 1.59 (1.16–2.18), 1.42 (0.87–2.31) and 1.28 (0.91–1.81). Time-to-event analysis showed a greater response with pindolol augmentation versus placebo (P = 0.04). There was significant heterogeneity between studies at some time points. Dropout rates did not significantly differ between treatment arms. This review suggests an overall beneficial clinical effect of pindolol augmentation, most clearly up to 4 weeks of treatment.

#### Key words

depressive disorder; pindolol; SSRI; systematic review

# Introduction

Despite advances in the treatment of depressive disorders, available antidepressants take at least 2–3 weeks to produce a substantial clinical response and are not effective in all patients (Blier and de Montigny, 1994). Several open-label studies have investigated the efficacy of pindolol in combination with sero-tonergic antidepressants, showing a more rapid onset of action and enhanced antidepressant effect (Artigas, *et al.*, 1994; Blier and Bergeron, 1995; Vinar, *et al.*, 1996). This could offer substantial clinical benefit in depressed subjects, particularly in those who are suicidal or restricting fluid and food intake as symptoms of their illness. However, results from randomised, placebo-controlled, double-blind studies of pindolol combination have been inconsistent, and no definite conclusion of its

effects has been established (McAskill, *et al.*, 1998). The review by Ballesteros and Callado (2004) included nine trials, showed equal tolerability and adverse event rate with pindolol versus placebo and suggested a beneficial effect of pindolol augmentation at 2 weeks but not at 4–6 weeks of treatment.

In addition to its ability to block  $\beta$ -adrenoceptors, pindolol also binds to serotonin<sub>1A</sub> (5-HT<sub>1A</sub>) receptors. Indeed, the clinical effect of pindolol augmentation of antidepressant treatment is hypothesised to be mediated by antagonism of 5-HT<sub>1A</sub> autoreceptors on 5-HT cell bodies. Animal electrophysiology studies show that 5-HT potentiating antidepressant drugs enhance neurotransmission across 5-HT synapses after chronic but not acute administration (de Montigny and Blier, 1984; Blier, *et al.*, 1990). 5-HT<sub>1A</sub> autoreceptors are involved in the inhibition of 5-HT cell firing and are activated by acute

Corresponding author: Richard Whale, IPGM, Brighton and Sussex Medical School, Falmer, Brighton BN1 9PH, UK. Email: richard.whale@brighton.ac.uk



Journal of Psychopharmacology 24(4) (2010) 513–520 © 2010 British Association for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, Los Angeles, London, New Delhi and Singapore 10.1177/0269881108097714 administration of 5-HT potentiating antidepressants such as selective serotonin reuptake inhibitors (SSRIs). Continued administration of the antidepressant leads to desensitisation of 5-HT<sub>1A</sub> autoreceptors resulting in greater enhancement of 5-HT neurotransmission by the antidepressant. Therefore, antagonism of the 5-HT<sub>1A</sub> receptor from the start of antidepressant treatment would be expected to produce an earlier and greater enhancement of serotonergic neurotransmission and antidepressant activity (Artigas, *et al.*, 1994).

This review aimed to investigate whether pindolol enhances the efficacy of antidepressant treatment in adult patients with depressive disorders at different time points up to 6 weeks.

## Methods

## Data source

The search strategy for identification of studies was as follows:

- 1) Electronic databases: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), incorporating results of group researches of MEDLINE (1990-April 2007), EMBASE (1990-April 2007), CINAHL (1990-April 2007), PsycLIT (1990-April 2007), PSYNDEX (1990-April 2007) and LILACS (1990-April 2007) was searched using the following terms: #45 (diagnosis field) = depression or depressive-disorder and # (intervention field) = pindolol or visken or viskaldix or visten or barbloc or novo-pindol or nu-pindol or durapindol or glauco-stulln or pectobloc or pinbelol or pindoptan or pindoreal or viskeen or decreton or hexapindol or bedrenal or betapindol or viskene or viskenit or viskezide or nitrisken. The Cochrane library was also searched using the same terms as for CCDANCTR excluding references tagged with sr-depress as these have come from CCDANCTR.
- References checking: The reference lists of all selected studies were inspected for more published reports and citations of unpublished research. In addition, other relevant papers and major textbooks that cover affective disorders were checked.
- Personal communications: To ensure all randomised trials are being identified, the authors of significant papers and other experts in the field were contacted as necessary.
- 4) Pharmaceutical companies: Pharmaceutical companies manufacturing antidepressant medication were contacted to find out if they knew of any published or unpublished randomised controlled trials (RCTs) relevant to this review. Reviewers RW and TT undertook this search.

## Study selection

Studies included in this review met the following criteria:

- 1) Types of studies: Prospective randomised controlled trials (RCTs).
- 2) Participants: All patients suffering from a depressive disorder according to explicit criteria, including major

depressive disorder (unipolar depressive disorder) and bipolar depressive disorder.

- Interventions: Studies comparing the effect of pindolol against placebo in combination with SSRIs for antidepressant treatment.
- 4) Outcome measures: Dichotomous clinical response, as defined by >50% depression scale score reduction. We intended to extract this data for different time points up to 6 weeks to examine differences of antidepressant effect between treatment arms.

The methodological quality of included studies was independently assessed by reviewers RW and TT. Quality was assessed according to the Cochrane criteria for quality assessment (Sackett, 1997), focussing particularly on the quality of the randomisation procedure and allocation concealment. On this basis, studies were given a quality rating of A (adequate), B (unclear) and C (inadequate). If the raters disagreed, the final rating was made by consensus with the involvement, if necessary, of another review group. Other key aspects of randomised controlled trial quality such as whether the trial was of a double-blind design and reporting of withdrawals and dropouts were assessed. Where adequate details of randomisation and other characteristics of trials were not provided, the authors were contacted to obtain further information.

#### Data extraction

Data were extracted about participant characteristics, intervention details and outcome measures from the included studies. Any disagreement was resolved by consensus discussions. Last observation carried forward was adopted for dropouts at all stages of trials. Dropouts were counted as non-responders in the binary efficacy outcome measure.

Data were entered into Review Manager 4.2 software by two reviewers using the duplicate data entry facility. For the binary efficacy outcome, a pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated using a fixed effects model. Heterogeneity between studies was assessed using the Q statistic (DerSimonian and Laird, 1986) and  $I^2$  (Higgins, et al., 2003). If significant heterogeneity was identified, sources were investigated. Random effects models were used routinely to investigate the sensitivity of results to the choice of statistical method. Outcome was measured at different time points up to 6 weeks (at 1, 2, 3, 4, 5 and 6 weeks). The influence of refractory depressive syndrome, severity of illness at admission to the trials, type and dose of serotonergic antidepressant and dose of pindolol on study outcome were intended to be explored. A time-to-event analysis was also undertaken, using a discrete logistic model, using cumulative response data at each weekly time point, to examine whether pindolol augmentation was associated with a greater response than placebo. The discrete logistic model accounted for trial as a fixed effect and examined the validity of the assumption of constant proportional hazards. The time-to-event analysis was conducted in SAS 9.1 (SAS Institute, Cary, North Carolina, USA).

# Results

Overall, 11 studies met criteria for inclusion in this review and their characteristics, including methodological quality, are shown in Table 1. Nine studies were identified from electronic databases Berman, *et al.* (1997, 1999), Bordet, *et al.* (1998), Maes, *et al.* (1999), Perez, *et al.* (1997, 1999), Tome, *et al.* (1997) and Zanardi, *et al.* (1997, 1998). For one additional study identified electronically but not including responder data in the paper, the authors were contacted who kindly supplied this data to us by email (Zanardi, *et al.*, 2001). One unpublished study was discovered by approaching pharmaceutical companies (Holland, *et al.*, 1997). Despite other companies planning such studies, no further evidence of completed trials was found.

Absolute continuous values of depression scale scores were not available in the published accounts of these identified studies, and key authors contacted were unwilling to share this data. Data availability at weekly time points up to 6 weeks varied between these studies. Only subjects fitting inclusion criteria for this review within each study were included (e.g., a mianserin treatment arm in the Maes, *et al.* study (1999) was excluded, as mianserin is not an SSRI), and we endeavoured

 Table 1
 Characteristics of randomised controlled trials including depressed patients comparing serotonin reuptake inhibitors with pindolol versus serotonin reuptake inhibitors with placebo, accepted for this reviews

Study	Included subjects	Age (years)	Duration (days)	Participant characteristics	Intervention	Dropouts (pindolol arm)	Method quality rating
Berman, <i>et al</i> . (1997)	43	18–70	42	DSMIV Major Depression HAMD (25 item) ≥18 Non-psychotic outpatients	Fluoxetine 20 mg + Pindolol 5 mg bd or 2.5 mg tds versus placebo	8 (3)	A
Berman <i>, et al</i> . (1999)	43	18-70	42	DSMIV Major Depression HAMD (25 item) ≥18 Non-psychotic outpatients (only new data from report included)	Fluoxetine 20 mg + Pindolol 2.5 mg tds vs placebo	9 (4)	A
Bordet, <i>et al</i> . (1998)	100	18–65	21	DSMIV Major Depression unipolar HAMD (17 item) ≥18 Non-psychotic in and out patients	Paroxetine 20 mg + Pindolol 2.5 mg tds vs placebo	20 (10)	A
Holland, <i>et al</i> . (1997)	164	18-65	42	ICD10 Depression MADRS ≥18 Non-psychotic outpatients	Paroxetine 20 mg + Pindolol 2.5 mg tds versus placebo	22 (11)	A
Maes, <i>et al</i> . (1999)	21	25–70	35	DSMIIIR Major Depression HAMD (17 item) ≥16 Inpatients	Fluoxetine 20 mg + Pindolol 2.5 mg tds versus placebo	not recorded	A
Perez, <i>et al</i> . (1997)	111	over 18	42	DSMIV Major Depression unipolar HAMD (17 item) ≥18 Non-psychotic outpatients	Fluoxetine 20 mg + Pindolol 2.5 mg tds versus placebo	22 (9)	A
Perez, <i>et al.</i> (1999)	80	18–65	10	DSMIV Major Depression HAMD(17 item) ≥16 Non-psychotic or bipolar outpatients Current episode resistant to SSRI but <9 months duration	SSRI + Pindolol 2.5 mg tds versus placebo	2 (1)	A
Готе, <i>et al</i> . (1997)	80	18-65	42	ICD10 Depression MADRS ≥18 Non-psychotic or bipolar outpatients	Paroxetine 20 mg + Pindolol 2.5 mg tds versus placebo	19 (8)	A
Zanardi, <i>et al</i> . (1997)	42	18–65	28	DSMIV Major Depression recurrent HAMD ≥18 Inpatients	Paroxetine 20 mg + Pindolol 2.5 mg tds versus placebo	0 (0)	A
Zanardi <i>, et al</i> . (1998)	72	18-65	42	DSMIIIR Major Depression HAMD ≥ 21 Delusion experience scale >3 Psychotic Inpatients Including bipolar	Fluvoxamine increased to 150 mg bd over 8 days + Pindolol 2.5 mg tds versus placebo	1 (1)	A
Zanardi <i>, et al</i> . (2001)	155	18-65	42	DSMIV Major Depression recurrent HAMD(21 item) ≥21 Inpatients Including bipolar and psychotic	Fluvoxamine increased to 150 mg bd over 8 days + Pindolol 2.5 mg tds versus placebo	5 (1)	A

not to count subjects twice within identified republished data (as with Berman, *et al.*, 1999). All studies used the Hamilton Depression Symptom Rating Scale (HAMD) except Holland, *et al.* and Tome, *et al.* who used the Montgomery Asberg Depression Rating Scale (MADRS). All studies allowed concomitant benzodiazepines only except the first Zanardi, *et al.* trials (1997, 1998) that allowed no concomitant medication and the later Zanardi, *et al.* trial (2001) that included a small group on lithium maintainance and allowed benzodiazepine use. The Zanardi, *et al.* (1997, 1998, 2001), Maes, *et al.* (1999) and Perez, *et al.* (1997, 1999) studies included a placebo run-in before starting antidepressant/pindolol.

Exceptions to available data on dichotomous 50% reduction in depression scale score at specific weekly time points were as follows. In the Bordet, *et al.* (1998) study, percent of patients 'remitting' was defined as a HAMD (17 item) score of  $\leq 10$ . This was deemed adequately equivalent to at least a 50% reduction in HAMD score and data at days 5, 10 and 21 were entered in this review at weeks 1, 2 and 3, respectively. For the Perez, *et al.* (1999) trial, number of 'responders' at day 10 was entered for day 14. For the included Zanardi, *et al.* studies (1997, 1998, 2001), numbers of responders at weekly time points were classified as those achieving a HAMD of <8. These assumptions made are all likely underestimates of actual 50% depression scale score reductions.

All included trials were assessed to have adequate quality of randomisation and allocation concealment and rated as 'A'. There was no disagreement about trial quality ratings between reviewers.

A total of 889 subjects were included in these trials with 435 receiving pindolol and 454 receiving placebo. Dichotomous outcomes of numbers of subjects in each arm reaching at least a 50% reduction in depression rating scale were available or interpretable (as above) for these trials, although not consistently at all time points up to 6 weeks. Figure 1 plots the data obtained for weeks 1-6 individually. The fixed effects pooled ORs (95% CI) for treatment after 1, 2, 3 and 4 weeks consistently favoured the pindolol treatment arm and were 2.39 (1.40-4.06), 2.39 (1.74-3.29), 1.94 (1.46-2.58) and 1.59 (1.16-2.18), respectively. The ORs (95% Confidence Interval) for weeks 5 and 6 were not statistically significant at 1.42 (0.87-2.31) and 1.28 (0.91-1.81), respectively, although the direction of the effect was towards benefit for pindolol. By week 6, the number of trials contributing data had reduced from 10 (at week 2) to 7, and the corresponding number of subjects included in the analysis had reduced from 710 at week 4 to 667 at week 6. Furthermore, the binomial distribution has a bigger variance when the incidence rate approaches 50%. Thus, the absence of evidence of effect at 5 and 6 weeks may be artefactual. Examining random effects models for pooled OR showed similar statistically significant beneficial effects of pindolol over placebo for weeks 1-4 (all CI > 1) only. The numbers needed to treat for weeks 1-4 are 16, 7, 7 and 12, respectively.

The hazard ratio for time to response for pindolol versus placebo augmentation was 1.26 (95%CI 1.01–1.58; P = 0.04),

modestly significantly favouring pindolol. For the proportional hazards assumption violation test, P = 0.96, indicating no evidence for a departure from linearity in effect. Figures 2 and 3 show the cumulative response and survival analysis graphs.

## Dropouts

In the trials that included data on dropouts (all except the Maes, *et al.* (1999) trial), 48/435 (11%) and 60/454 (13%) dropped out of the pindolol and placebo arms, respectively (chi squared = 0.99, P = 0.31). An investigator group effect is observed, with the Zanardi, *et al.* studies (1997, 1998, 2001) showing much lower dropout rates of 2% for pindolol and 3% for placebo arms. Descriptions of dropouts in these included studies were not consistently adequate to undertake further sensitivity analysis (all dropouts in either arm were assumed to be non-responders).

## Heterogeneity


There was statistically significant (at P < 0.1 level) heterogeneity between the trial-specific estimates at weeks 2, 3, 4 and 5 with varying degrees of inconsistency between studies measured by  $I^2$ . The later Berman, *et al.* trial (1999) was most consistently discrepant (favouring placebo). Random effects estimates were calculated to take account of the heterogeneity and were broadly similar to the fixed effects estimates at all time points.

We explored the potential role of several study level characteristics in exploring this heterogeneity:

Refractory depressive syndrome Most studies included a mix of refractory and non-refractory subjects. Perez, et al. (1999) examined augmentation of existing SSRI treatment to which subjects had not responded to a reasonable trial, with no overall significant positive outcome. Perry, et al. (2004) described no significant benefit of randomised pindolol augmentation in patients who had not responded to an adequate previous trial of an SSRI (this study was not included in this review as the authors have not clarified whether these subjects were included in the previously published Berman, et al. studies that were undertaken around the same time). Maes, et al. (1999), however, included a subanalysis of treatment resistant subjects (non-response to a single previous adequate trial with an antidepressant) comprising 15 patients and showed a significant benefit of pindolol augmentation in this small group. Sokolski, et al. (2004) also showed a beneficial response to once daily pindolol augmentation (7.5 mg) in a small group (n = 9) of previous SSRI non-responders (the authors have not supplied further details of this trial to enable inclusion in this review). The overall influence of refractory syndrome on pindolol response is therefore unclear. The response to pindolol in non-refractory subjects was unable to be ascertained.

tudy r sub-categor	Pindolol n/1	Placeto	OR (fixed) 95% Cl	Weight	OR (fixed) 95% Cl
erman 1997	1/23	0/20		2.70	2.73 [0.11, 70.92]
foliand 1997 lerez 1997	7/81	9/81 1/56		64.20	0.77 [0.27, 2.17]
ome 1997	4/55 17/40	7/40		4.97	4.81 [0.47, 39.88] 3.48 [1.28, 9.78]
anardi 1997 Iordet 1998	7/21 8/50	0/21 3/50		1.78	22.24 [1.18, 420.34] 2.14 [0.50, 9.07]
Seet ibrand	0/36	0/36			Not estimable
Berman 1999 Zanardi 2001	0/22	1/21 -		0.11 2.19	Not estimable 0.30 [0.01, 7.88] 12.54 [0.66, 237.14]
etal (95% Ct)	395	414	•	100.00	2.39 [1.40, 4.04]
est for hetero	5 (Pindolo(), 21 (Placebo) geneby: Chi <sup>p</sup> = 10.38, df = 7 (P = 0.17), P = 3 effect: Z = 3.21 (P = 0.001)			COMMENT	
leview:	Pindolol augmentation of SSRI treatment	0,01	0.1 1 10 Favours placebo Favours pin	100 Solol	
Comparison: Dutcome:	02 comparison between pindolol and place 01 Odda ratio of dichotomous response	too al week 2 of thats			
tudy r sub-category	Pindolal n/N	Placebo nºl	OR (fixed) 95% CI	Weight 55	OR (fixed) 95% Cl
erman 1997 Iolland 1997	4/23 33/81	4/20		7.14	0.84 [0.18, 3.92]
erez 1997	12/55	4/86		6.26	1.66 [0.87, 3.18] 3.63 [1.09, 12.06]
ome 1997 anardi 1997	23/40	15/40 2/21		12.88	2.25 [0.92, 5.52] 12.67 [2.33, 68.93]
ordet 1998	12/21 24/50	13/80		13.65	2.63 [1.13, 6.09]
anardi 1998 erman 1999	€/3€ 2/22	1/36 4/21		- 1.68 7.82	7.00 (0.80, 61.66) 0.43 (0.07, 2.61)
erez 1999	5/40	5/40	-+	8.84	1.00 [0.27, 3.76]
anardi 2001	26/67	11/88		11.75	4.44 [1.99, 9.88]
otal (95% CI) otal events: 14 est for hetero;	435 7 (Pindolot), 83 (Placebo) genety: ChP + 15.59, df + 9 (P + 0.08), P + 4 effect: Z = 5.34 (P < 0.00001)	484	•	100.00	2,39 [1.74, 3.29]
ust for overall	effect: Z = 5.34 (P < 0.00001)	0.01	0.1 10	100	
rview:	Pindolol augmentation of SSRI treatment		Favours placebo Favours pint	01010	
omparison: utcome:	03 comparison between pindolol and place 01 Odds ratio of dichotomous response	ebo at week 3 of trials			
tudy r sub-category	Pindolal n/lt	placebo n?i	OR (fixed) 95% CI	Weight %	OR (fixed) 95% CI
erman 1997 Iolland 1997	6/23 46/81	7/20 42/02		8.02 26.12	0.66 [0.10, 2.42] 1.25 [0.60, 2.32]
erez 1997	28/55	17/56		11.98	2.38 [1.09, 5.18]
ome 1997 anardi 1997	26/40	19/40		9.63	2.05 (0.84, 5.04) 4.00 (1.11, 14.43)
lordet 1998	31/80	30/60	-	16.81	1.09 [0.49, 2.43]
anardi 1998 erman 1999	21/36	5/36		- 0.02 5.05	0.00 [2.74, 27.52]
anardi 2001	7/22 B1/67	9/21 41/88		5.05	0.62 (0.18, 2.16) 3.65 (1.81, 7.36)
anarol 2001					
otal (95% CI) otal events: 23 est for hetero;	398 10 (Pindolo), 177 (placebo) penety: Ch <sup>4</sup> = 20.89, df + 8 (P = 0.007), P = effect: Z = 4.80 (P < 0.00001)	414 81.7% 0.01	0.1 1 10 Favours clacébo Favours pin	100.00 100	1.94 [1.46, 2.88]
otal (55% CI) otal events: 23 est for hetero; est for overall eviow: omparison:	395 10 (Pindolol), 177 (placebo) cenety: Chi <sup>a</sup> = 20.59. df = 5 (P = 0.007), # =	414 81.7% 0.01		100.00 100	
otal (55% CI) otal events: 23 est for heteroj est for overall eview: imparison: utcome: udgy	39.5 10 (Pinoclul), 177 (placeb) panety: Ch <sup>2</sup> 2 0.58, df 4 (P = 0.007), P = effect: Z = 4.80 (P < 0.0001) Prodolol augmentation of SSRI treatment 64 companion between pinoticil and place 01 Octos ratio of dichotomous response Prodolol	414 81.7% 0.01		100.00 100	
otal (55% CI) otal sventa: 23 est for hetero; est for overall eview: organison: utcome: tudy sub-catepory erman 1997	395 (Prodol), 177 (placeb) pendy, Ch <sup>2</sup> + 20, 8, 4* 4 (P + 0.007), P + effect: 2* + 40 (P + 0.0001) Prodolf augmentation of 53% (reatment 04 comparison between prodolf and place 01 Oce ratio of schotness response 01 Oce ratio of schotness response 02 Oce ratio of schotness	414 017% 001 bo at week 4 of trials Placebo not 7/20	Favours placebo Favours pin OR (fixed)	100.00 t00 dolot Weight 55 7.90	0R (fixed) Sfis Cl 0.89 [0.28, 3.48]
otal (95% CI) otal events: 21 est for hetero; est for overail eview: imparison: itcome: udy sub-catepory erman 1997 oland 1997	391 (0, (Pencic)), 177 (sister) pencic), CIP = 20, 55, 47 = 0, (P = 0.007), P = effect: 2 = 4.80 (P < 0.0001) Product appendiation of 550 treatment. Conception of sister product and pencic 01.005 ratio of sister pencic 01.005 ratio of	414 81.7% 0.01 0.01 Placebo 0.01 7/20 50/82	Favours placebo Favours pin OR (fixed)	100.00 100 dolot 55 7.90 29.79	0% (best) 5% Cl 0.99 (0.28, 3.49)
otal (55% CI) otal events: 21 est for hetero; est for overall eview: imparison: utcome: sub-catepory erman 1997 otano 1997 erez 1997	395 (Prodol), 177 (placeb) pendy, Ch <sup>2</sup> + 20, 8, 4* 4 (P + 0.007), P + effect: 2* + 40 (P + 0.0001) Prodolf augmentation of 53% (reatment 04 comparison between prodolf and place 01 Ode rate of schotness response 01 Ode rate of schotness response 02 Ode	414 017% 001 bo at week 4 of trials Placebo not 7/20	Favours placebo Favours pin OR (fixed)	100.00 t00 dolot Weight 55 7.90	OR (bes) 55% C 0.5% C 0
otal (95% CI) otal events: 22 est for heteroj est for overall sview: mparison: utcome: utjy erman 1997 otano 1997 erez 1997 ome 1997 anardi 1997	398         398           genetic         177 (pisseate)           genetic         28 × 20.05 gf = 0,07 × 0.0001)           effect:         2 × 4.00 (0+ 0.00001)           Prodotil expensation of SSI treatment           do comparises theore principid and expenses           Podotil expenses           0.000 statio of sSI treatment           0.000 statio           8/2.3           8/2.4           30/18           30/18           20/28	414 81.7% 0.09 00 at week 4 of trials Placebo n/1 90/42 20/42 24/40 10/21	Favours placebo Favours pin OR (fixed)	100.00 100 dolot 5 7.90 29.79 16.04 1.45 2.09	08 (bee) 58% 0 0.59 (0.28, 0.48] 0.59 (0.28, 0.48] 1.58 (0.47, 0.48] 1.58 (0.47, 0.44] 1.48 (0.47, 0.34] 1.48 (0.47, 0.34)
otal (55% CI) otal events: 22 est for hetero; est for overall evideox: income: usty erman 1997 erman 1997 ome 1997 ome 1997 anardi 1995	395 (Prodob), 177 (pised) parenty, Ch * 30, 8), of * 6 (P * 0.007), P = effect; 2 * 4 & (P * 6.0001) Prodobl augmentation of SSN (resomer: 64 comparison between prodobl and pised 10 does into of distributions in segoral Prodobl 87,28 51/15 51/15 51/15 27,25	414 81.7% 0.01 00 at week 4 of trials Placebo 7/20 80/21 22/26 22/26 22/26 22/26	Favours placebo Favours pin OR (fixed)	100.00 100 dolof 7.90 29.79 16.04 11.65 8.08 6.47	08 (thest) 55% Cl 0.99 [0.28, 3,48] 0.99 [0.28, 2,68] 1.08 [0.48, 2,68] 1.48 [0.48, 2,68] 1.48 [0.47, 3,44] 1.48 [0.27, 3,44] 1.48 [0.27, 3,44] 1.48 [0.27, 3,44]
otal (85% CI) otal events: 21 exi for heteroj est for overall sview: suparison: stoome: usy erman 1997 olano 1997 anardi 1998 anardi 1998 anardi 1998 anardi 2001	391 (1) (Poecici), 177 (sister) entrop: CP = 20.05, 41 = 0, 9 = 0.007), # = entrop: 2 = 2.80 (# < 6.0001) Podotal expensation of 550 tostament. Conservation tost protosta at operation 1) Ods valio of dichotomous response Prototal 8/741 8/743 3/743 3/743 2/7142 8/747 8/747	414 81.7% bo at week 4 of triats Pisotbo not 20/42 22/44 22/44 22/44 22/44 24/40 16/34 16/36 16/24	Favours placebo Favours pin OR (fixed)	100.00 100.00 dolot Weight 55 5 16.04 11.65 6.47 12.65 12.41	08 (fores) 55% Cl 0.59 (0.28, 0.48) 1.94 (1.44, 2.48) 0.59 (0.28, 0.48) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.43) 1.44 (1.17, 18, 48) 0.75 (1.18, 10.29) 0.43 (0.13, 1.44) 0.15 (0.13, 1.44)
Total (95% Ct) Total events: 22 Total events: 22 Fest for heteroy fest for heteroy fest for overall without and uccome: tudy r sub-category bernan 1997 Earardi 1997 Earardi 1997 Earardi 1998 Earardi 1998 Earardi 1998 Earardi 2001 Cotal (95% Ct) Cotal events: 22	395     395     4000000, 177 (bitseld)     400000, 177 (bitseld)     400000, 177 (bitseld)     4000000000000000000000000000000000	414 81.7% 0.01 00 at week 4 of trials Placebo 0.01 22/40 20/40 20/	Favours placebo Favours pin OR (fixed)	100.00 tb0 dolot 7.90 29.79 16.04 11.65 6.47 12.65	08 (foet) 55% Cl 0.9 (0.28, 0.48) 1.0 (0.48, 0.48) 1.48 (0.47, 0.44) 1.48 (0.47, 0.44) 1.48 (0.47, 0.44) 4.78 (1.08, 0.43) 4.78 (1.08, 0.43) 4.78 (1.08, 0.43) 4.78 (1.08, 0.43)
Total (95% Ct) Total events: 22 Total events: 22 Fest for heteroy fest for heteroy fest for overall without and uccome: tudy r sub-category bernan 1997 Earardi 1997 Earardi 1997 Earardi 1998 Earardi 1998 Earardi 1998 Earardi 2001 Cotal (95% Ct) Cotal events: 22	398         398           peneto:         177 (piseate)           peneto:         24.90 (P < 0.0001)	414 01.7% 0.01 bo at week 4 of trains Placebo actio 20.92 20	GR (fixed) 55% Cl	100.00 100 000 100 100 100 100 10	08 (fores) 55% Cl 0.59 (0.28, 0.48) 1.94 (1.44, 2.48) 0.59 (0.28, 0.48) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.43) 1.44 (1.17, 18, 48) 0.75 (1.18, 10.29) 0.43 (0.13, 1.44) 0.15 (0.13, 1.44)
Intel (95% CI) Total events: 22 east for heteroy east for heteroy east for heteroy east for heteroy outcome: tudy r sub-category leman 1997 lanardi 1997 lanardi 1997 lanardi 1998 lanardi 1998 lanardi 1998 lanardi 2001 catel events: 22 lanardi 2001 catel events: 22 la	395     395     4000000, 177 (bitseld)     400000, 177 (bitseld)     400000, 177 (bitseld)     4000000000000000000000000000000000	414 0.01 bo at week 4 of trians Placebo notio notio notio notio notio notio notio notio notio notio notio notio 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 24,444 24,44424,444 24,444 24,4444 24,4444 24,4444424,4444 24,44444 24,4444444444	Revours placebo Favours pla OR (fixed) 5555 c1	100.00 100 000 100 100 100 100 10	08 (fores) 55% Cl 0.59 (0.28, 0.48) 1.94 (1.44, 2.48) 0.59 (0.28, 0.48) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.43) 1.44 (1.17, 18, 48) 0.75 (1.18, 10.29) 0.43 (0.13, 1.44) 0.15 (0.13, 1.44)
otal (\$5% CI) bala events: 22 est for hetero; est for netros impartison: doome: uty sub-category erra: 1997 offant 1997 anaroli 1997 an	393     10 (Percici), 177 (sistead)     20 # 20 (5), 41 + 0 ≠ 0.007), # +     4frett 2 = 4.80 (4 + 6.0001)     7	414 0.01 bo at week 4 of trians Placebo notio notio notio notio notio notio notio notio notio notio notio notio 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 22,44 24,444 24,44424,444 24,444 24,4444 24,4444 24,4444424,4444 24,44444 24,4444444444	GR (fixed) 55% Cl	100.00 100 000 100 100 100 100 10	08 (fores) 55% Cl 0.59 (0.28, 0.48) 1.94 (1.44, 2.48) 0.59 (0.28, 0.48) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.44) 1.84 (0.47, 2.43) 1.44 (1.17, 18, 48) 0.75 (1.18, 10.29) 0.43 (0.13, 1.44) 0.15 (0.13, 1.44)
otal (\$5% CI) otal events: 22 est for heteroy est for overall view: imparison: iccome: usy exb-category ere 1697 ere 169	393     393     394	414 0.017% 0.01 00 at week 4 of trials Placebo not 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 22/84 26 22/84 26 22/84 26 22/84 26 20 20 20 20 20 20 20 20 20 20 20 20 20	Parours placebo Favours pla OR (fined) 0855 C1 0855 C1 0855 C1 0 08 (fined) 08 (fined)	100.00 tb0 weight 5 7,50 25,79 16,64 12,45 12,45 12,45 12,45 100.00 t00 t00 Weight 18,85	03 (fores) 55% 0 0.55 (0.28, 3.45) 0.55 (0.28, 3.45) 1.69 (0.48, 3.05) 1.48 (0.47, 3.44) 1.48 (0.47, 3.44) 1.48 (0.47, 3.44) 1.48 (0.47, 3.44) 1.48 (1.15, 14.45) 1.49 (1.16, 2.18) 0.69 (1.16, 2.18) 08 (fores) 55% 0 1.09 (0.38, 3.42)
otal (SS15 CI) otal events: 22 set for heleroy ear for overall earlier overall earlier overall earlier overall sub-category otal store: usy sub-category one 1997 anarol 1907 anarol 1908 errors: store earlier store earlier anarol 1908 errors: store earlier anarol 1908 errors: store earlier anarol 1908 errors: store earlier anarol 1908 errors: store earlier anarol 1908	393     10 (Percici), 177 (sisteaded)     sentery: CV = 20.55, cf = 0         20.077, / F =         47.055, cf = 0         20.077, / F =	414 81.7% bo at week 4 of triats Pisosbo noti 20/82 20/84 20/84 20/84 16/82 364 22% 0.00 0.00 0.00 0.00 0.00 0.00 0.00	Parours placebo Favours pla OR (fined) 0855 C1 0855 C1 0855 C1 0 08 (fined) 08 (fined)	100.00 tb0 0000	08 (fores) 55% Cl 0.59 (0.28, 0.48) 0.50 (0.28, 0.48) 1.50 (0.28, 0.48) 1.60 (0.28, 0.48) 1.81 (0.47, 0.44) 1.84 (0.47, 0.44) 1.84 (0.47, 0.44) 1.84 (0.47, 0.44) 1.84 (0.47, 0.44) 1.85 (1.16, 0.18) 0.85 (0.48) 0.85 (0.48) 0.8
otal (\$5% CI) otal events: 21 est for heleroy est for heleroy est for overail view: usy events usy events usy events toome: toome: usy events toome: toome: usy events toome: toome: toome: usy events toome: usy events toome: to	393     393     394     394     395	414 01.7% 0.01 bo at week 4 of frians Placebo ent 22.740 22.740 22.740 22.740 22.740 22.740 22.740 22.740 22.740 22.741 22.741 0.00 0.00 0.01 0.020 0.01 0.020 0.021 0.020 0.021 0.020 0.021 0.020 0.021 0.020 0.021 0.020 0.021 0.0	Parours placebo Favours pla OR (fined) 0855 C1 0855 C1 0855 C1 0 08 (fined) 08 (fined)	100.00 tb0 cetter 7,90 29,79 14,04 100.00 100.00 tb0 tb0 tb0 tb0 tb0 tb0 tb0 t	08 (foed) 55% C1 0.99 (0.38, 0.48) 1.99 (0.38, 0.48) 1.48 (0.47, 0.34) 0.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.49, 0.49) 0.48 (0.18, 0.44) 1.49 (1.16, 0.18) 0.48 (0.18, 0.44) 1.49 (1.16, 0.18) 08 (foed) 55% C1 1.49 (0.38, 0.41) 1.59 (1.16, 0.18) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 08 (foed) 0.48 (0.18, 0.47) 0.48 (0.48, 0.47) 0.48 (0.47, 0.47)
obal (55% CD) abal (55% CD) abal vontex 2 volenci magarison willy aba-category usy aba-category aban (1997 aban (1997) aban (1	398     399	414 81.7% 0.01 0.01 0.01 0.01 0.02	Parours placebo Favours pla OR (fined) 0855 C1 0855 C1 0855 C1 0 08 (fined) 08 (fined)	100.00 tb0 cetes	08 (bee) 58% 0 0.96 (0.28, 3.48) 1.94 (1.44, 2.88) 0.95 (0.28, 3.48) 1.86 (0.47, 3.44) 1.46 (0.42, 3.43) 4.48 (1.47, 3.44) 1.48 (0.47, 3.44) 1.48 (1.42, 1.43) 1.48 (1.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.44) 1.49 (1.44, 2.18) 0.41 (0.44, 2.18) 1.99 (0.44, 1.47, 4.48) 1.99 (1.44, 1.47, 4.48) 1.99 (1.44, 1.48)
obai (65% C) data event. 21: 21 data event. 21: 21 data event. 21: 21 event. 21: 21 event. 21: 21 event.	393     393     394     394     395	414 01.7% 0.01 bo at week 4 of trials 7/20 60/82 22/40 20/40 22/40 20/40	Parours placebo Favours pla OR (fined) 0855 C1 0855 C1 0855 C1 0 08 (fined) 08 (fined)	100.00 tb0 cetter 7,90 28,79 14,04 100.00 12,64 12,44 100.00 tb0 tb0 tb0 tb0 tb0 tb0 tb0 t	08 (foed) 55% C1 0.99 (0.38, 0.48) 1.99 (0.38, 0.48) 1.48 (0.47, 0.34) 0.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.48 (0.47, 0.34) 1.49 (1.16, 0.164) 0.41 (0.35, 0.43) 1.49 (0.48, 0.44) 1.49 (0.48, 0.44) 1.59 (1.16, 0.164) 08 (foed) 55% C1 1.49 (0.38, 0.43) 1.59 (0.38, 0.44) 1.59 (0.38, 0.44) 1.59 (0.38, 0.44) 1.59 (0.38, 0.44) 1.59 (0.48, 0.44) 1.59 (0.48, 0.44) 1.59 (0.48, 0.44) 1.59 (0.48, 0.44) 0.48 (0.48,
stal (65% C) stal (65% C) stal events, 21, 22 stal events, 21, 22 stal events, 21, 22 stal events, 22	398     399	414 01.7% 0.01 bo at week 4 of trials Placebo 0.02 22/40 22/40 22/40 22/40 12/21 42/30 12/21 42/30 12/21 42/30 22/5 0.01 20/30 22/5 0.01 20/30 22/5 22/5 0.01 20/30 22/5 22/5 0.01 20/30 22/5 22/5 0.01 20/30 22/5 22/5 0.01 20/30 2	Parours placebo Favours pla OR (fbed) 5555 C1 0 0 0 0 0 0 0 0 0 0 0 0 0	100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00	08 (bee) 58% 0 0.96 (0.28, 3.48) 1.94 (1.44, 2.88) 0.95 (0.28, 3.48) 1.86 (0.47, 3.44) 1.46 (0.42, 3.43) 4.46 (1.42, 3.43) 4.48 (1.42, 1.43) 1.48 (0.47, 3.44) 1.48 (1.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.44, 2.18) 1.99 (0.44, 1.47, 4.48) 1.99 (0.44, 4.48)
stal (65% C) stal (65% C) stal events, 21, 22 stal events, 21, 22 stal events, 21, 22 stal events, 22	398     399	414 01.7% 0.01 bo at week 4 of trians Placebo 00.22 22.74 20.70	Parcurs placebo Favours pla OR (fixed) SESS CI Favours placebo Favours pla CR (fixed) SESS CI Favours placebo Favours pla	100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00	08 (bee) 58% 0 0.96 (0.28, 3.48) 1.94 (1.44, 2.88) 0.95 (0.28, 3.48) 1.86 (0.47, 3.44) 1.46 (0.42, 3.43) 4.46 (1.42, 3.43) 4.48 (1.42, 1.43) 1.48 (0.47, 3.44) 1.48 (1.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.44, 2.18) 1.99 (0.44, 1.47, 4.48) 1.99 (0.44, 4.48)
para (p35 trug) set of the result of the re	338     339	414 01.7% 0.01 bo at week 4 of trians Placebo 00.22 22.74 20.70	Parours placebo Favours pla OR (fbed) 5555 C1 0 0 0 0 0 0 0 0 0 0 0 0 0	100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00	08 (bee) 58% 0 0.96 (0.28, 3.48) 1.94 (1.44, 2.88) 0.95 (0.28, 3.48) 1.86 (0.47, 3.44) 1.46 (0.42, 3.43) 4.46 (1.42, 3.43) 4.48 (1.42, 1.43) 1.48 (0.47, 3.44) 1.48 (1.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.42, 1.43) 1.49 (1.44, 2.18) 0.41 (0.44, 2.18) 1.99 (0.44, 1.47, 4.48) 1.99 (0.44, 4.48)
stati (55% C) Lat events 22 22 24 24 24 24 24 24 24 24	338     339	414 01.7% 0.01 Placebo n/1 7/20 50/22 20/22	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 100.0	0R (fores) 55% C1 0.39 (0.28, 0.48) 1.39 (0.28, 0.48) 1.48 (0.47, 0.48) 1.48 (0.47, 0.48) 1.48 (0.47, 0.48) 0.48 (1.07, 0.48) 1.48 (1.7, 18, 48) 0.48 (1.12, 18, 48) 0.48 (1.12, 18, 48) 1.48 (1.14, 0.14) 1.48 (1.14, 0.14) 0.48 (0.48, 0.48) 1.48 (1.14, 0.14) 0.48 (0.48, 0.48) 1.49 (0.48, 0.48) 1.42 (0.47, 4.48) 1.42 (0.47, 0.25) 0.48 (0.48, 0.48) 1.42 (0.47, 0.25) 0.48 (0.48, 0.48) 0.48 (0
bal (65% CP) Laf events 21 21 of event	393     393     394     394     395	414 01.7% 0.01 bo at week 4 of trians Placebo 01/21 27/40	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 topo	0R (fores) 55% C1 0.96 (0.28, 0.48) 0.95 (0.28, 0.48) 1.09 (0.48, 0.48) 1.48 (0.47, 0.48) 1.48 (0.47, 0.48) 0.48 (0.12, 0.48) 1.48 (0.27, 0.48) 0.48 (0.13, 0.48) 1.49 (1.16, 0.18) 0.48 (0.13, 0.48) 1.49 (1.16, 0.18) 0.48 (0.13, 0.48) 1.49 (1.16, 0.18) 0.48 (0.13, 0.48) 1.49 (1.16, 0.18) 0.48 (0.13, 0.48) 1.49 (0.48, 0.48) 1.40 (0.48, 0.48) 1.40 (0.47, 0.31) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.80 (0.48) 0.48 (0.13, 1.48) 0.48 (0.1
para (effe to (effect)) effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect effect of the effect of the effect of the effect of the effect effect of the effect of the effect of the effect of the effect effect of the effect of the effect of the effect of the effect of the effect effect of the effect of the e	338     339     33	414 01.7% 0.01 00 at week 4 of trials Placebo 01/21 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/22 10/20	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 100.00 100 0000 100 100 100	08 (fbeet) 55% C1 0.99 (1.46, 2.49) 0.99 (0.28, 2.49) 1.09 (0.28, 2.49) 1.09 (0.28, 2.49) 1.09 (0.42, 2.49) 1.49 (1.7, 13, 49) 0.48 (0.47, 3.49) 1.49 (1.7, 13, 49) 1.49 (1.7, 13, 49) 1.49 (1.14, 2.14) 1.49 (1.14, 2.14) 1.49 (1.14, 2.14) 1.49 (0.48, 2.49) 1.49 (0.49, 2.49) 1.49 (0.49, 2.49) 1.42 (0.47, 2.41) 1.42 (0.47, 2.41) 08 (fbeet) 55% C1 0.41 (0.15, 2.41) 08 (fbeet) 55% C1 0.41 (0.15, 2.41) 08 (fbeet) 55% C1 0.41 (0.15, 2.41) 08 (fbeet) 55% C1 0.41 (0.15, 2.41) 0.41 (0.15, 2.41) 0.41 (0.15, 2.41)
said Shi Chi ala e venta 22 vieno: tean to to construct 20 vieno: tean to construct 20 kab - tean to c	338     339	414 01.7% 0.01 Placebo n/1 7/20 50/22 2/40 10/21 10/21 10/21 10/21 10/21 10/21 10/20 2/40 10/20 1	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 100.00 100.00 100.00 11.43 11.43 10.00 100.00 100.00 100 100.00 100	08 (fores) 55% C1 0.99 (0.28, 0.48) 1.99 (0.28, 0.48) 1.09 (0.48, 0.48) 1.09 (0.48, 0.48) 1.48 (0.47, 0.48) 0.48 (0.17, 0.48) 0.48 (0.17, 0.48) 0.48 (0.12, 0.49) 1.69 (1.24, 0.18) 0.48 (0.12, 0.49) 1.69 (1.24, 0.18) 0.48 (0.12, 0.49) 1.09 (0.48, 0.41) 1.69 (1.24, 0.18) 0.48 (0.12, 0.44) 1.49 (1.24, 0.18) 0.41 (0.12, 0.49) 0.42 (0.12, 1.49) 0.42 (0.12, 1.49) 0.41 (0.12, 1.49) 0.42 (0.12, 1.49) 0.42 (0.12, 1.49) 0.43 (0.12, 1.49) 0.43 (0.12, 1.49) 0.43 (0.12, 1.49) 0.45 (0.12,
stal (65% C) stal (65% C) stal events 21 stal events 21 st	398     399     39	414 0.017% 0.017% 0.017% 0.017% 0.021	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 tb0 color 7.50 25.75 26.04 11.64 2.4.5 100.00 tcol 100 tco	08 (fore) 55% 0 0.94 (1.44, 2.48] 0.95 (0.28, 3.48] 1.95 (0.28, 3.48] 1.48 (0.47, 3.48] 1.49 (0.48, 3.48] 1.49 (0.48, 4.48] 1.40 (0.47, 2.31] 08 (fore) 55% 0 0.48 (0.48, 3.48] 1.42 (0.47, 2.31] 08 (fore) 55% 0 0.41 (0.12, 1.42] 1.42 (0.47, 2.48] 1.42 (0.47, 2.48] 0.43 (0.48, 2.48] 1.43 (0.48, 2.48] 0.44 (0.48, 2.48] 1.44 (0.47, 2.48] 1.45 (0.48, 2.48] 1.45 (0.48, 2.48] 1.48 (0.48, 2.48
star (55% C) star (55% C) star (55% C) star (55% C) star (55% C) star (55% C) star (15% C) st	338         338           peneto:         177 (pissed)           peneto:         20.85 of = 0, P = 0.007), P = 0.007), P = 0.007), P = 0.007), P = 0.007, P = 0.007), P = 0.007, P = 0.007), P = 0.007, P = 0.	414 01.7% 0.01 bo at week 4 of trials Placabo noti 7/20 80/82 24/40 16/22 46/88 22% 0.01 10/20 24/40 10/20 24/40 10/20 24/40 10/20	Parours placebo Favours pla OR (fixed) 5555 cl Favours placebo Favours pla C1 Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 5555 cl Favours placebo Favours placebo OR (fixed) 08 (fixed)	100.00 100.00 100.00 100 100 100 1	08 (fbert) 55% C1 0.99 (0.28, 0.48) 0.99 (0.28, 0.48) 1.09 (0.28, 0.48) 1.09 (0.28, 0.48) 1.09 (0.48, 0.48) 1.09 (0.48, 0.48) 1.48 (1.7, 18.48) 0.48 (0.47, 18.48) 1.48 (1.7, 18.48) 1.48 (0.47, 2.31] 08 (fbert) 55% C1 08 (fbert) 55% C1 08 (fbert) 08 (fbert) 1.48 (0.47, 2.31] 08 (fbert) 08 (fbert) 1.48 (0.47, 2.31] 08 (fbert) 1.48 (0.47, 2.31] 08 (fbert) 1.48 (0.47, 2.31] 08 (fbert) 1.48 (0.47, 2.31] 08 (fbert) 1.48 (0.47, 2.31]
Jack (SSI) (2) all all and all all all all all all all all all al	398     399     39	414 0.017% 0.017% 0.017% 0.017% 0.021	Parours placebo Favours pla OR (fixed) 5555 cl Tavours placebo Favours pla C1 To Pavours placebo Favours platebo OR (fixed) 555 cl Tavours placebo Favours platebo OR (fixed) 555 cl Tavours placebo Favours platebo OR (fixed) 08 (fixed) 08 (fixed) 08 (fixed) 08 (fixed) 08 (fixed) 08 (fixed) 08 (fixed) 09 (fixed) 09 (fixed) 00 (fixed	100.00 tb0 color 7.50 27.50 27.50 27.50 24.64 100.00 12.45 12.45 100.00 t00 t00 t00 t00 t00 t00 t00	08 (fore) 55% 0 0.94 (1.44, 2.48] 0.95 (0.28, 3.48] 1.95 (0.28, 3.48] 1.48 (0.47, 3.48] 1.49 (0.48, 3.48] 1.49 (0.48, 4.48] 1.40 (0.47, 2.31] 08 (fore) 55% 0 0.48 (0.48, 3.48] 1.42 (0.47, 2.31] 08 (fore) 55% 0 0.41 (0.12, 1.42] 1.42 (0.47, 2.48] 1.42 (0.47, 2.48] 0.43 (0.48, 2.48] 1.42 (0.47, 2.48] 0.43 (0.48, 2.48] 1.43 (0.48, 2.48] 1.44 (0.47, 2.48] 1.45 (0.48, 2.48] 1.45 (0.48, 2.48] 1.48 (0.48, 2.48

**Figure 1** Plots of dichotomous response to randomised pindolol versus placebo augmentation of serotonin reuptake inhibitors in depressed subjects by weeks 1–6. Response is defined as a 50% improvement in depressive scale score. *n*, number of responders; *N*, number of patients per group; OR, odds ratio.



**Figure 2** Cumulative response (50% improvement of depression scale score) to augmentation of serotonin reuptake inhibitors with randomised pindolol (diamonds) versus placebo (squares) in depressed subjects by time. \*P < 0.025, \*\*P < 0.001; chi squared for pindolol versus placebo.

**Severity of illness at admission to the trials** Inpatients [as included in trials by Zanardi, *et al.* (1997, 1998, 2001) and Maes, *et al.* (1999)] appeared to show more beneficial responses to pindolol than outpatients included in other trials. This could equally be an investigator group effect. The only trial examining solely psychotic depressed subjects showed overall significantly beneficial effects with pindolol at weeks 3 and 4 (Zanardi, *et al.*, 1998). This delay in response to week 3 may relate to the titration period of fluvoxamine in this trial. Data available were not adequate to correlate response with depression symptom scale scores at inclusion. The study by Tome,




Figure 3 Survival plot of response (50% improvement of depression scale score) to augmentation of serotonin reuptake inhibitors with randomised pindolol (red line) versus placebo (blue line) in depressed subjects by time.

*et al.* (1997) showed a site effect within the trial, with the better responding clinic having less severe and chronic depression and more previously untreated subjects. Studies including subjects with higher range baseline HAMD scores (mean > 30) were Berman, *et al.* (1997, 1999) and Zanardi, *et al.* (1998, 2001), which showed no within group consistent effect of pindolol augmentation. The overall influence of severity of illness on pindolol response is therefore also unclear.

**Type and dose of serotonergic antidepressant** The only consistent effect of type of SSRI was that the two trials using fluvoxamine [both by Zanardi, *et al.* (1998, 2001)] had associated significant effect of adding pindolol. This could also be a site effect. Other trials showed varying effects within SSRI groups. Plenge and Mellerup (2003) have argued that using paroxetine in combination with pindolol is the most effective SSRI choice, but this is not consistently borne out from the data presented here. The influence of dose of SSRIs could not be examined because of no variation between trials.

**Dose of pindolol** Only one included study (Berman, *et al.*, 1997) varied in the dose of pindolol used from 2.5 mg tds, with 9 of 43 subjects receiving 5 mg bd. The overall influence of pindolol dose could, therefore, not be examined although PET imaging evidence suggests that the dose 2.5 mg tds does not produce reliable occupancy of 5-HT<sub>1A</sub> receptors in the human brain (Rabiner, *et al.*, 2001). Sokolski, *et al.* (2004) used once daily pindolol dosing of 7.5 mg with beneficial effects (further details of this trial were not supplied to enable inclusion).

**Other factors** Other relevant factors influencing heterogeneity may include the use of placebo run-in (which six trials included as above), but this appeared to have no influence and was deemed to be unimportant when analysed using survival analysis by Perez, *et al.* (2001). In a descriptive review, Segrave and Nathan (2005) concluded that untreated patients with few previous depressive episodes, less duration of current episode and no other psychiatric comorbidity would be more likely to respond to pindolol augmentation, but this is not clearly supported from the data in this review and would need to be examined in specific trials to be clarified. Genetic influences, such as the 5-HT transporter 44 base pair insertion/ deletion polymorphism (Smeraldi, *et al.*, 1998), could also influence response.

# Conclusions

The use of pindolol to augment SSRI treatment has theoretic appeal and support from animal experimental studies. However, the results of clinical randomised trials have appeared inconsistent. This review includes a larger study sample than those previously published (e.g., Ballesteros and Callado (2004) who included 594 subjects). The findings modestly support augmentation of newly started serotonergic antidepressant treatment with pindolol, particularly where fast onset is important, as it appears to increase the rate of response to treatment (with a favourable NNT of 7 at week 2), and it appears as well tolerated as placebo. The potential adverse effects of  $\beta$ -adrenoceptor blockade (particularly in respiratory and cardiac disorders) need to be weighed with the relatively transient benefit in antidepressant response.

Exploration of the greater heterogeneity at weeks 2–4, particularly the influence of selected illness and drug variables, was not conclusive because of limited published data and no further individual data available from study groups. No clear influence of type of patient (refractory depression or severity of depression at trial inception), choice of SSRI or pindolol dose on response was observed. The most influential predictor of outcome appeared to be study group.

Analysis by time to event indicates a benefit for pindolol without evidence of a departure from constant proportional hazards. However, when we consider the evidence from contingency table analysis at weeks 5 and 6 on their own, we do not see evidence of a treatment effect. The apparent loss of a clinically beneficial effect of augmentation after 4 weeks, if not a statistical artefact (as above), may reflect further synaptic adaptations that override initial enhanced 5-HT neurotransmission effects of 5-HT<sub>1A</sub> autoreceptor blockade with pindolol. Tome, *et al.* (1997) and Berman, *et al.* (1999) indicated that withdrawal of pindolol after week 6 had no significant effect on depression scale scores, which influences how pindolol may be clinically used.

Wider clinical experience, beyond trial boundaries, has not overall led to favourable reports on the antidepressant effect of augmentation with pindolol. Perhaps, this is to be expected as antidepressant treatments already have overall observed small effects over placebo in clinical populations (Kirsch, *et al.*, 2002) and compliance with taking pindolol three times per day could be poor. Clinicians adding pindolol following initial nonresponse to an antidepressant [as in the second Perez, *et al.* study (1999)] may also be unlikely to see further improvement, akin to the period after 4 weeks of pindolol augmentation of initial treatment when no further benefit is observed. A larger daily dose of pindolol may give greater clinical benefit as implied from imaging studies (Rabiner, *et al.*, 2001).

Further larger trials and continuous data from existing pindolol studies, unavailable to the current authors, are required to confirm or refute the findings of this review. Additional studies could more specifically examine the time of onset of effect of pindolol, with daily monitoring of mood. More relevant to clinical practice, studies of pindolol versus placebo augmentation with more homogenous patient populations (e.g., severity of illness, refractory syndrome, naivety to treatment) would more clearly define who is likely to respond. This review focussed solely on clinical response, whereas longer term remission may be more clinically important and valuably studied.

Whether or not the beneficial effect of pindolol on rate of antidepressant response is due to 5-HT<sub>1A</sub> receptor blockade remains to be established. If this is the case, development of

more specific autoreceptor antagonists with greater clinical utility than pindolol, such as a longer half life, would be beneficial. Pindolol may have other properties, such as acting as a nitrogen species scavenger (Fernandes, *et al.*, 2005), which could explain these effects.

## References

- Artigas, F, Perez, V, Alvarez, E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248–251.
- Ballesteros, J, Callado, LF (2004) Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79: 134–147.
- Berman, RM, Darnell, AM, Miller, HL, Anand, A, Charney, DS (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37–43.
- Berman, RM, Anand, A, Cappiello, A, Miller, HL, Hu, XS, Oren, DA, et al. (1999) The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebocontrolled trial. Biol Psychiatry 45: 1170–1177.
- Blier, P, de Montigny, C, Chaput, Y (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51 (Suppl.): 14–20.
- Blier, P, de Montigny, C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220–226.
- Blier, P, Bergeron, R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217–222.
- Bordet, R, Thomas, P, Dupuis, B (1998) Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 155: 1346–1351.
- de Montigny, C, Blier, P (1984) Effects of antidepressant treatments on 5-HT neurotransmission: electrophysiological and clinical studies. Adv Biochem Psychopharmacol 39: 223–239.
- DerSimonian, R, Laird, N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
- Fernandes, E, Gomes, A, Costa, D, Lima, JL (2005) Pindolol is a potent scavenger of reactive nitrogen species. Life Sci 77: 1983–1992.
- Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
- Holland, C, Edwards, T, Hughes, S (1997) A multi-centre, doubleblind placebo-controlled study to investigate the effect of pindolol on the onset of antidepressant activity of paroxetine in the treatment of depression. Trial BRL 29060. SmithKline Beecham.
- Kirsch, I, Moore, TJ, Scoboria, A, Nicholls, SS (2002) The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 5: http:// journals.apa.org/prevention/.
- Maes, M, Libbrecht, I, Van Hunsel, F, Campens, D, Meltzer, HY (1999) Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177–182.
- McAskill, R, Mir, S, Taylor, D (1998) Pindolol augmentation of antidepressant therapy. Br J Psychiatry 173: 203–208.
- Perry, EB, Berman, RM, Sanacora, G, Anand, A, Lynch-Colonese, K, Charney, DS (2004) Pindolol augmentation in depressed patients

resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 65: 238–243.

- Perez, V, Gilaberte, I, Faries, D, Alvarez, E, Artigas, F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349: 1594–1597.
- Perez, V, Soler, J, Puigdemont, D, Alvarez, E, Artigas, F (1999) A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 56: 375–379.
- Perez, V, Puiigdemont, D, Gilaberte, I, Alvarez, E, Artigas, F; Grup de Recerca en Trastorns Afectius (2001) Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 21: 36–45.
- Plenge, P, Mellerup, ET (2003) Pindolol and the acceleration of the antidepressant response. J Affect Disord 75: 285–289.
- Rabiner, EA, Bhagwagar, Z, Gunn, RN, Sargent, PA, Bench, CJ, Cowen, PJ, et al. (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158: 2080–2082.
- Sackett, D (1997) The Cochrane Collaboration Handbook. Oxford: The Cochrane Collaboration.
- Segrave, R, Nathan, PJ (2005) Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol 20: 163–174.

- Sokolski, KN, Conney, JC, Brown, BJ, DeMet, EM (2004) Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Res 125: 81–86.
- Smeraldi, E, Zanardi, R, Benedetti, F, Di Bella, D, Perez, J, Catalano, M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3: 508–511.
- Tome, MB, Isaac, MT, Harte, R, Holland, C (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 12: 81–89.
- Vinar, O, Vinarova, E, Horacek, J (1996) Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression. Homeost Health Dis 37: 93–95.
- Zanardi, R, Artigas, F, Franchini, L, Sforzini, L, Gasperini, M, Smeraldi, E, *et al.* (1997) How long should pindolol be associated with paroxetine to improve the antidepressant response. J Clin Psychopharmacol 17: 446–450.
- Zanardi, R, Franchini, L, Gasperini, M, Lucca, A, Smeraldi, E, Perez, J (1998) Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 18: 441–446.
- Zanardi, R, Serretti, A, Rossini, D, Franchini, L, Cusin, C, Lattuada, E, et al. (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50: 323–330.

I chose this article because it is a systematic review consisting of 11 total articles for review that included randomized RCTs, a total patient number of 889 participants, discussing the efficacy of pindolol in use with SSRIs. The cohort group was of the largest size within a fairly recent time frame. Also, I appreciated that this meta-analysis specifically discussed how treatment with pindolol dwindled after week 4, this could be efficacious as a consideration for stopping therapy with pindolol and SSRI combination as the effects wear off quickly. Also, the discussion of the refractory depressive syndrome is discussed as part of this review, saying that for patients who did not initially respond to SSRI treatment in the first place, would not respond to the addition of pindolol to their depression medication regimen. Also, while this systematic review is on the older side, it was the largest cohort available and I felt it lent the highest level of evidence in this particular PICO instance. Ultimately this systematic review did point out that the transient benefit of pindolol in accelerating the patient's response to antidepressants may not be a strong enough benefit when weighing against possible beta-adrenoreceptor blockade adverse effects. While pindolol may not be efficacious long-term, it at least can help the patient to possibly feel less depressive symptoms at the beginning of their new SSRI treatment, where sometimes that may take more than 3 weeks to set in depending, of course, upon the patient themselves.